文献速递主动脉疾病

血管外科学会血管质量倡议B型夹层TEVAR项目30天结局

Thirty-day outcomes from the Society for Vascular Surgery Vascular Quality Initiative thoracic endovascular aortic repair for type B dissection project.
PubMed 文献 · J Vasc Surg · 2019-01-01

基于前瞻性质量改进注册数据库,收集40家机构397例B型夹层TEVAR患者(急性204例、慢性193例),比较30天结局。无并发症急性夹层30天死亡率为5.8%,治疗时机与结局无显著差异。

要点

  • 急性B型夹层TEVAR后30天死亡率9.3%,慢性夹层5.2%,差异无统计学意义。
  • 无并发症急性夹层TEVAR后30天死亡率为5.8%,再干预率5.8%。
  • 无并发症急性夹层治疗时机(≤48小时至<30天)与30天死亡或严重并发症无显著差异。

核心结论

  • 急性B型夹层患者较慢性患者呈现更高的30天死亡率和更低的免于再干预率趋势。
  • 无并发症急性B型夹层TEVAR后30天死亡率为5.8%,治疗时机未见对死亡率或再干预的明确影响模式。

研究设计与样本

  • 前瞻性质量改进注册数据库研究,纳入40家机构的397例B型夹层TEVAR患者(急性204例、慢性193例)。
  • 比较急性(<30天)与慢性夹层患者,并按有无并发症及无并发症急性夹层治疗时机分层分析。

关键数值与推荐

  • 急性夹层定义:<30天;慢性夹层为≥30天。
  • 无并发症急性夹层按治疗时机分为≤48小时、>48小时至<7天、≥7天至≤14天、>14天至<30天。
  • 技术成功率包括覆盖主要破口;主要结局为30天死亡、脊髓缺血、卒中、逆行A型夹层和再干预。

临床怎么用

  • TEVAR治疗B型夹层技术成功率高,但急性期30天死亡和再干预风险仍值得关注。
  • 无并发症急性B型夹层治疗时机选择需个体化,30天内不同时间窗结局相似。
  • 需长期随访评估治疗时机对无并发症急性B型夹层的远期影响。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of the Society for Vascular Surgery Vascular Quality Initiative thoracic endovascular aortic repair (TEVAR) for dissection project is to assess the effectiveness of TEVAR for type B dissection by evaluation in a prospective quality improvement registry. Here we describe the project cohort and 30-day outcomes of TEVAR for both acute dissection (AD) and chronic dissection (CD) patients and focus specifically on outcomes of uncomplicated AD patients based on timing of treatment. METHODS: Summary statistics were performed comparing patients with AD (<30 days) and patients with CD. Both groups were further divided into those with complicated (ie, malperfusion or rupture) or uncomplicated presentation. Further subdivision of the uncomplicated AD patients into treatment at ≤48 hours, >48 hours to <7 days, ≥7 days to ≤14 days, and >14 days to <30 days was performed. Kaplan-Meier analysis was performed for 30-day survival and freedom from reintervention. RESULTS: Data for 397 patients (204 AD patients and 193 CD patients) were collected from 40 institutions. Overall, AD patients were younger than CD patients (58.8 vs 62.2 years; P = .003). Technical success, including coverage of the primary entry tear, was 98.0% for AD patients and 99.0% for CD patients, with a trend toward a higher 30-day mortality in AD patients (AD, 9.3%; CD, 5.2%; P = .126). Any degree of procedure-related spinal cord ischemia occurred in 4.4% of AD patients vs 2.1% of CD patients (P = .261), with a deficit at discharge in 3.4% of AD patients vs 0.5% of CD patients (P = .068). Disabling stroke occurred in 2.5% of AD patients vs 1.6% of CD patients (P = .725); retrograde type A dissection occurred in 1.1% of AD patients vs 2.6% of CD patients (P = .412). There was a trend toward a lower freedom from reintervention in AD patients (90.7% vs 94.8%; P = .13). In uncomplicated AD patients, rapid aortic expansion was more common in the treatment groups of ≥7 days to ≤14 days and >14 days to <30 days compared with those treated within 7 days of dissection (P = .042). The uncomplicated AD cohorts based on timing of treatment were otherwise similar in demographics and presentation, with no significant differences in 30-day mortality or serious complications, such as spinal cord ischemia, stroke, or retrograde type A dissection. The 30-day reintervention rate for uncomplicated AD patients was 5.8%, with no apparent differences in reintervention rates according to timing of treatment of initial TEVAR. CONCLUSIONS: As expected, AD patients demonstrated a trend toward a higher 30-day mortality and lower freedom from reintervention compared with CD patients. Mortality at 30 days after TEVAR for uncomplicated AD was 5.8%, and there were no clear patterns in mortality or reintervention based on timing of treatment. Further study and evaluation at longer follow-up are needed to determine the impact of timing of intervention in uncomplicated AD patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang GJ, Cambria RP, Lombardi JV, et al. Thirty-day outcomes from the Society for Vascular Surgery Vascular Quality Initiative thoracic endovascular aortic repair for type B dissection project. J Vasc Surg. 2019. PMID: 30798842. doi:10.1016/j.jvs.2018.06.203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。